Ltr Pharma Limited has released a press release.
LTR Secures First U.S. Commercial Agreement for ROXUS
Earlier from Ltr Pharma
- SPONTAN® Phase II interim data demonstrates rapid onset and pharmacokinetic profile addressing FDA Pre-IND requirements across adult and ≥65 populations
- SPONTAN Phase II data show rapid onset, support FDA pathway
- SPONTAN Phase II Clinical Study Completes Recruitment